Portola Pharma (PTLA) Tops Q1 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Portola Pharmaceuticals Reports First Quarter 2015 Financial Results and Provides Corporate Update
May 6, 2015 4:01 PM EDTSOUTH SAN FRANCISCO, Calif., May 6, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq: PTLA) today provided a corporate update and reported its financial results for the first quarter ended March 31, 2015.
"This is a monumental year for the company," said William Lis, chief executive officer of Portola. "We are now approximately one year from the potential launch of our first commercial product, andexanet alfa, in 2016 followed by a second product launch with betrixaban in 2017. Additionally, we are advancing a third clinical-stage program in hematologic cancers with our dual-acting agent, cerdulatinib. Each of these products is wholly-owned,... More
